CNS Pharmaceuticals Reports $4.9 Million Net Loss and Announces New Corporate Strategy

CNS Pharmaceuticals, Inc. reported a net loss of approximately $4.9 million for the first quarter of 2026, an increase from a net loss of about $4.3 million during the same period in 2025. The company's total operating expenses rose to approximately $5.0 million, compared to $4.3 million in the prior year, driven primarily by increased research and development costs and higher professional expenses. General and administrative expenses also saw a rise, totaling approximately $1.4 million, up from $1.1 million in the previous year, reflecting increased legal, marketing, and insurance costs.

The company's financial position showed a significant decline in cash and cash equivalents, which decreased to approximately $2.95 million as of March 31, 2026, down from $7.2 million at the end of 2025. This decline was attributed to cash used in operating activities, which amounted to approximately $4.6 million for the quarter. CNS Pharmaceuticals also reported a working capital deficit of about $504,000. The company has historically funded its operations through debt and equity sales, and during the first quarter, it raised approximately $501,000 from the sale of 178,933 shares of common stock under its ATM Sales Agreement.

In terms of strategic developments, CNS Pharmaceuticals announced a new corporate strategy in March 2026, focusing on innovative therapies for serious diseases. This strategy includes a shift from a singular focus on glioblastoma multiforme to exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin. The company has also undergone significant organizational changes, including the appointment of Rami Levin as the new CEO and the hiring of several key executives, including a new Chief Financial Officer and Chief Medical Officer.

Operationally, CNS Pharmaceuticals has been working on completing and closing out the clinical trial for Berubicin, with patient enrollment and treatment now complete. The company’s research and development expenses reflect ongoing activities related to this trial, alongside increased headcount expenses. As of March 31, 2026, the company had 811,449 shares of common stock issued and outstanding, a notable increase from 632,516 shares at the end of 2025, indicating a potential increase in shareholder engagement.

Looking ahead, CNS Pharmaceuticals has alleviated concerns regarding its ability to continue as a going concern following a private placement financing that closed on May 5, 2026, which raised approximately $22.5 million. The company plans to use these proceeds to identify and secure rights to development-stage assets and advance any assets obtained. However, management has acknowledged the need for additional capital to support future operations and execute its business plan, indicating that further fundraising may be necessary.